-
摘要: 新诊断的急性白血病患者在早期即疾病确诊后的4周内危重症发生是影响疾病预后和患者长期生存的重要因素。早期危重症主要包括高白细胞血症、弥散性血管内凝血、呼吸窘迫综合征、肿瘤溶解综合征以及严重出血等，早期危重症未及时识别和处理，则很快会导致早期死亡的发生，从而抵消由于药物的普及和诊疗规范的推进带来的长期生存获益。对于急性白血病早期危重症患者，早期识别并了解这些危重症的临床表现和防治措施，积极处理相关并发症，有助于提高患者的生存率和改善预后。Abstract: The presence of critical illness in patients with newly diagnosed acute leukemia within 4 weeks after diagnosis is a significant determinant of prognosis and long-term survival. Early critical illnesses mainly include hyperleukocytosis, disseminated intravascular coagulation, respiratory distress syndrome, tumor lysis syndrome, and severe bleeding. Failure to promptly recognize and treat early critical illness can rapidly lead to premature mortality, negating the benefits derived from drug advancements and improved diagnostic and treatment standards. Timely identification, comprehension of clinical manifestations, implementation of preventive measures, management of complications are pivotal for enhancing the survival rate and prognosis of patients.
-
Key words:
- acute leukemia /
- early stage /
- critical illness
-
-
[1] Cheng S, Pole JD, Sung L. Early deaths in pediatric acute leukemia: a population-based study[J]. Leuk Lymphoma, 2014, 55(7): 1518-1522. doi: 10.3109/10428194.2013.850685
[2] Atallah E, Cortes J, O'Brien S. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia[J]. Blood, 2007, 110(10): 3547-3551. doi: 10.1182/blood-2007-06-095844
[3] Giammarco S, Chiusolo P, Piccirillo N, et al. Hyperleukocytosis and leukostasis: management of a medical emergency[J]. Expert Rev Hematol, 2017, 10(2): 147-154. doi: 10.1080/17474086.2017.1270754
[4] Nan X, Qin Q, Gentille C, et al. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis-a retrospective study from a tertiary center[J]. Leuk Lymphoma, 2017, 58(9): 1-11.
[5] Perissinotti AJ, Bishop MR, Bubalo J, et al. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel[J]. Cancer Treat Rev, 2023, 120: 102603. doi: 10.1016/j.ctrv.2023.102603
[6] Bewersdorf JP, Zeidan AM. Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?[J]. Cells, 2020, 9(10): 2310. doi: 10.3390/cells9102310
[7] Shallis RM, Stahl M, Bewersdorf JP, et al. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes benefits[J]. Expert Rev Hematol, 2020, 13(5): 489-499. doi: 10.1080/17474086.2020.1751609
[8] Göçer M, Kurtoǧlu E. Effect of prophylactic leukapheresis on early mortality and overall survival in acute leukemia patients with hyperleukocytosis[J]. Ther Apher Dial, 2021, 25(5): 697-703. doi: 10.1111/1744-9987.13645
[9] Franchini M, Di Minno MN, Coppola A. Disseminated intravascular coagulation in hematologic malignancies[J]. Semin Thromb Hemost, 2010, 36(4): 388-403. doi: 10.1055/s-0030-1254048
[10] Kongstad C, Mikkelsen TS, Hvas AM. Disseminated intravascular coagulation in children with cancer: A systematic review[J]. Pediatr Hematol Oncol, 2020, 37(5): 390-411. doi: 10.1080/08880018.2020.1733717
[11] Songthawee N, Chavananon S, Sripornsawan P, et al. Prevalence and risk factors of disseminated intravascular coagulation in childhood acute lymphoblastic leukemia[J]. Pediatr Res, 2023, 94(2): 588-593. doi: 10.1038/s41390-023-02475-8
[12] Martí-Carvajal AJ, Anand V, Solà I. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia[J]. Cochrane Database Syst Rev, 2015, 2015(6): CD008562.
[13] Hua VM, Abeynaike L, Glaros E, et al. Necrotic platelets provide a procoagulant surface during thrombosis[J]. Blood, 2015, 126(26): 2852-2862. doi: 10.1182/blood-2015-08-663005
[14] Anderson DR, Leader A, Karrison TG, et al. D-dimer as a predictor of thrombotic events during early acute lymphoblastic leukemia therapy[J]. Blood, 2020, 136(Suppl 1): 5-6.
[15] Wang TF, Makar RS, Antic D, et al. Management of hemostatic complications in acute leukemia: guidance from the SSC of the ISTH[J]. J Thromb Haemost, 2020, 18(12): 3174-3183. doi: 10.1111/jth.15074
[16] Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab[J]. Blood, 2017, 129(10): 1275-1283. doi: 10.1182/blood-2016-09-736686
[17] de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin[J]. Blood, 2008, 111(7): 3395-3402. doi: 10.1182/blood-2007-07-100669
[18] Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia[J]. Br J Haematol, 2019, 187(2): 157-162. doi: 10.1111/bjh.16151
[19] 马媛媛, 沈建良. 急性早幼粒细胞白血病患者诱导治疗中出现分化综合征的多因素分析[J]. 中华老年多器官疾病杂志, 2014, 13(10): 755-757.
[20] Larson RS, Tallman MS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment[J]. Best Pract Res Clin Haematol, 2003, 16(3): 453-461. doi: 10.1016/S1521-6926(03)00043-4
[21] Chaoui D, Legrand O, Roche N, et al. Incidence and prognostic value of respiratory events in acute leukemia[J]. Leukemia, 2004, 18(4): 670-675. doi: 10.1038/sj.leu.2403270
[22] Azoulay E, Canet E, Raffoux E. Dexamethasone in patients with acute lung injury from acute monocytic leukaemia[J]. Eur Respir J, 2011, 39(3): 648-653.
[23] Atallah E, Cortes J, O'Brien S, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia[J]. Blood, 2007, 110(10): 3547-3355. doi: 10.1182/blood-2007-06-095844
[24] Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America[J]. Clin Infect Dis, 2011, 52(4): e56-e93. doi: 10.1093/cid/cir073
[25] Ewig S, Glasmacher A, Ulrich B, et al. Pulmonary infiltrates in neutropenic patients with acute leukemia during chemotherapy: outcome and prognostic factors[J]. Chest, 1998, 114(2): 444-451. doi: 10.1378/chest.114.2.444
[26] Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification[J]. Br J Haematol, 2004, 127(1): 3-11. doi: 10.1111/j.1365-2141.2004.05094.x
[27] Belay Y, Yirdaw K, Enawgaw B. Tumor Lysis Syndrome in Patients with Hematological Malignancies[J]. J Oncol, 2017, 2017: 9684909.
[28] Mato AR, Riccio BE, Qin L, et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy[J]. Leuk Lymphoma, 2006, 47(5): 877-883. doi: 10.1080/10428190500404662
[29] Truong TH, Beyene J, Hitzler J, et al. Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome[J]. Cancer, 2007, 110(8): 1832-1839. doi: 10.1002/cncr.22990
[30] Perissinotti AJ, Bishop MR, Bubalo J, et al. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel[J]. Cancer Treat Rev, 2023, 120: 102603. doi: 10.1016/j.ctrv.2023.102603
[31] Cheng CL, Li CC, Hou HA, et al. Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults[J]. BMC Cancer, 2015, 15: 344. doi: 10.1186/s12885-015-1376-9
[32] Wu SY, Short NJ, Nasr L, et al. Central Nervous System Prophylaxis and Treatment in Acute Leukemias[J]. Curr Treat Options Oncol, 2022, 23(12): 1829-1844. doi: 10.1007/s11864-022-01032-5
[33] Chern JJ, Tsung AJ, Humphries W, et al. Clinical outcome of leukemia patients with intracranial hemorrhage. Clinical article[J]. J Neurosurg, 2011, 115(2): 268-272. doi: 10.3171/2011.4.JNS101784
[34] Dayyani F, Mougalian SS, Naqvi K, et al. Prediction model for mortality after intracranial hemorrhage in patients with leukemia[J]. Am J Hematol, 2011, 86(7): 546-549. doi: 10.1002/ajh.22031
-
计量
- 文章访问数: 1209
- PDF下载数: 2112
- 施引文献: 0
下载: